肺复康方联合埃克替尼治疗气阴两虚痰瘀毒结型中晚期非小细胞肺癌临床研究

发布时间：2018-06-11 18:02

本文选题：肺复康方 + 埃克替尼　；参考：《湖南中医药大学》2016年硕士论文

【摘要】：研究目的:观察肺复康方联合埃克替尼治疗中晚期非小细胞肺腺癌提高患者生活质量、降低毒副反应、延长患者生存期及延缓耐药等方面的疗效,为中医肿瘤工作者提供有效的经验方剂。研究方法:预期入组符合要求的病例共60例,设治疗组(肺复康方联合盐酸埃克替尼组)30例和对照组(盐酸埃克替尼组)30例。按照入院先后顺序随机列入治疗组和对照组。对照组服用盐酸埃克替尼(商品名凯美纳),125mg,口服,每日3次,连续服用至病情进展或发生不能耐受的不良反应;治疗组口服凯美纳,用法及用量同上,并配合肺复康方治疗,水煎服,每日一剂,每次200ml,每日3次。治疗期间不再接受任何其他抗肿瘤治疗,治疗4周后进行疗效评价。根据症状积分、卡氏评分等指标观察生活质量改善情况,根据RECIST1.1版实体瘤的疗效评价标准、肿瘤标志物等指标观察近期疗效,根据皮疹、腹泻等观察毒副反应,根据血常规、肝肾功能、心电图等观察安全性情况。研究结果:60例患者入组本次临床观察研究,最终共纳入60例患者进行医学统计,其中治疗组、对照组各30例。结果显示:肺复康方联合埃克替尼与单纯埃克替尼相比较,在改善患者临床症状、提高患者生活质量、减轻毒副反应等方面,治疗组显著优于对照组,两组比较差异具有统计学意义(P0.05)且两组的近期疗效无明显差异(P0.05),且治疗组安全性良好。研究结论:肺复康方联合埃克替尼治疗中晚期非小细胞肺腺癌在改善患者临床症状、提高患者生活质量、减轻患者毒副反应等方面疗效均优于单纯埃克替尼组,且安全性良好,值得在临床上推广。
[Abstract]:Objective: to observe the effect of Feifukang recipe combined with Ektinib on improving the quality of life, reducing side effects, prolonging survival time and delaying drug resistance in patients with advanced non-small cell lung adenocarcinoma. To provide Chinese medicine oncology workers with effective empirical prescription. Methods: a total of 60 patients who were expected to meet the requirements were divided into treatment group (30 cases) and control group (30 cases). They were randomly divided into treatment group and control group according to the order of admission. The control group was treated with epitinib hydrochloride (125mg, commodity name), three times a day, continuously until the disease progressed or the side effects were intolerable, while the treatment group was treated with the same dosage and the same dosage as Kemena, and was treated with Feifukang recipe. Decoction of water, one dose daily, 200 ml each time, 3 times a day. No other anti-tumor therapy was accepted during the treatment and 4 weeks after treatment was evaluated. The improvement of quality of life was observed according to symptom score, Karnoff score and so on. According to the evaluation criteria of the curative effect of RECIST 1.1 solid tumor, tumor markers and other indexes, the short-term curative effect was observed, the side effects were observed according to rash and diarrhea, and the blood routine was used to observe the improvement of quality of life. The safety of liver and kidney function, electrocardiogram and so on were observed. Results A total of 60 patients were enrolled in this clinical study, including 30 cases in the treatment group and 30 cases in the control group. The results showed that the treatment group was superior to the control group in improving the clinical symptoms, improving the quality of life, alleviating the side effects and so on. The difference between the two groups was statistically significant (P0.05). There was no significant difference in the short-term curative effect between the two groups, and the safety of the treatment group was good. Conclusion: the efficacy of Feifukang decoction combined with Ektinib in the treatment of advanced non-small cell lung adenocarcinoma is superior to that of Ektinib alone in improving the clinical symptoms, improving the quality of life and alleviating the side effects of the patients, and the safety is good. It is worth popularizing in clinic.
【学位授予单位】：湖南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R734.2

【相似文献】